CHARLES SCHWAB INVESTMENT MANAGEMENT INC - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 247 filers reported holding SAGE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$8,416,952
-54.2%
408,987
+4.6%
0.00%
-60.0%
Q2 2023$18,392,719
+13.7%
391,168
+1.5%
0.01%0.0%
Q1 2023$16,172,097
+10.0%
385,417
-0.0%
0.01%0.0%
Q4 2022$14,705,869
-0.5%
385,576
+2.2%
0.01%0.0%
Q3 2022$14,780,000
+23.8%
377,415
+2.1%
0.01%
+25.0%
Q2 2022$11,940,000
+34.6%
369,650
+38.0%
0.00%
+33.3%
Q1 2022$8,869,000
-19.5%
267,945
+3.4%
0.00%0.0%
Q4 2021$11,020,000
-2.8%
259,034
+1.2%
0.00%
-25.0%
Q3 2021$11,341,000
-27.0%
255,933
-6.4%
0.00%
-20.0%
Q2 2021$15,530,000
-22.0%
273,355
+2.7%
0.01%
-28.6%
Q1 2021$19,916,000
-11.2%
266,072
+2.6%
0.01%
-22.2%
Q4 2020$22,437,000
+43.5%
259,349
+1.4%
0.01%
+28.6%
Q3 2020$15,640,000
+48.7%
255,889
+1.2%
0.01%
+40.0%
Q2 2020$10,517,000
+48.9%
252,916
+2.8%
0.01%
+25.0%
Q1 2020$7,064,000
-59.5%
245,934
+1.9%
0.00%
-55.6%
Q4 2019$17,422,000
-47.7%
241,330
+1.7%
0.01%
-55.0%
Q3 2019$33,292,000
-19.2%
237,304
+5.5%
0.02%
-20.0%
Q2 2019$41,199,000
+21.7%
225,019
+5.7%
0.02%
+13.6%
Q1 2019$33,860,000
+89.4%
212,885
+14.1%
0.02%
+57.1%
Q4 2018$17,876,000
-28.7%
186,607
+5.1%
0.01%
-17.6%
Q3 2018$25,080,000
-6.6%
177,551
+3.5%
0.02%
-15.0%
Q2 2018$26,847,000
-28.8%
171,509
-26.7%
0.02%
-31.0%
Q1 2018$37,682,000
+20.9%
233,945
+23.6%
0.03%
+16.0%
Q4 2017$31,169,000
+231.3%
189,230
+25.3%
0.02%
+212.5%
Q3 2017$9,409,000
-14.5%
151,026
+9.3%
0.01%
-20.0%
Q2 2017$11,005,000
+17.8%
138,179
+5.1%
0.01%
+11.1%
Q1 2017$9,342,000
+40.9%
131,440
+1.2%
0.01%
+28.6%
Q4 2016$6,630,000
+35.3%
129,847
+22.1%
0.01%
+16.7%
Q3 2016$4,900,000
+128.9%
106,387
+49.8%
0.01%
+100.0%
Q2 2016$2,141,000
+22.8%
71,041
+30.6%
0.00%
+50.0%
Q1 2016$1,744,000
-25.1%
54,379
+36.2%
0.00%
-33.3%
Q4 2015$2,328,000
+50.8%
39,930
+9.5%
0.00%
+50.0%
Q3 2015$1,544,000
+6.3%
36,477
+83.3%
0.00%0.0%
Q2 2015$1,453,000
+261.4%
19,895
+148.7%
0.00%
+100.0%
Q1 2015$402,000
+37.2%
8,0000.0%0.00%
Q4 2014$293,0008,0000.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
RTW INVESTMENTS, LP 5,149,482$105,976,3402.24%
Palo Alto Investors LP 1,005,776$20,698,8701.96%
Boxer Capital, LLC 1,094,000$22,514,5201.20%
Bellevue Group AG 3,513,351$72,304,7641.16%
PDT Partners, LLC 181,625$3,737,8430.47%
EASTERLY INVESTMENT PARTNERS LLC 195,643$4,026,3330.44%
Harvest Investment Services, LLC 30,302$623,6150.40%
Simplify Asset Management Inc. 120,030$2,470,2170.28%
SAMLYN CAPITAL, LLC 739,867$15,226,4630.25%
CAXTON ASSOCIATES LP 68,035$1,400,1600.19%
View complete list of SAGE THERAPEUTICS INC shareholders